Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

Samuel J. Klempner, Andrea P. Myers, Gordon Mills, Shannon N. Westin

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an exquisitely chemo-sensitive disease with response rates of over 75% in the upfront setting. Despite this, due to high rates of recurrence and development of chemo-resistance, the overall survival of EOC remains about 25%. Thus, there is a great need for new therapeutic approaches to render more durable responses. Based on preclinical and early phase clinical studies, key targeted pathways include targets that drive angiogenesis and chemo-resistance. Receptor tyrosine kinases and non-receptor tyrosine kinases play important roles in these processes and several small molecule tyrosine kinase inhibitors (TKIs) are in clinical development. Areas covered: This review summarizes clinical rationale, mechanisms of action and clinical data for the TKIs under evaluation in the Phase III setting for EOC. Expert opinion: Despite reasonable preclinical activity, small molecule TKIs are unlikely to improve patient survival as single agent therapies in an unselected EOC population. Incorporation of tissue evaluation during ongoing clinical trials is required to identify molecularly defined groups that respond to single agents and direct rational combination strategies based on mechanisms of resistance to improve outcomes in EOC.

Original languageEnglish (US)
Pages (from-to)2171-2182
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number16
DOIs
StatePublished - Oct 21 2013
Externally publishedYes

Fingerprint

Protein-Tyrosine Kinases
Therapeutics
Survival
Expert Testimony
Receptor Protein-Tyrosine Kinases
Ovarian epithelial cancer
Cause of Death
Neoplasms
Clinical Trials
Recurrence
Population

Keywords

  • angiogenesis
  • ovarian cancer
  • Phase III
  • signaling
  • targeted therapy
  • tyrosine kinase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. / Klempner, Samuel J.; Myers, Andrea P.; Mills, Gordon; Westin, Shannon N.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 16, 21.10.2013, p. 2171-2182.

Research output: Contribution to journalReview article

@article{37e13b7b7c394b299f3b38e5e88a403d,
title = "Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer",
abstract = "Introduction: Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an exquisitely chemo-sensitive disease with response rates of over 75{\%} in the upfront setting. Despite this, due to high rates of recurrence and development of chemo-resistance, the overall survival of EOC remains about 25{\%}. Thus, there is a great need for new therapeutic approaches to render more durable responses. Based on preclinical and early phase clinical studies, key targeted pathways include targets that drive angiogenesis and chemo-resistance. Receptor tyrosine kinases and non-receptor tyrosine kinases play important roles in these processes and several small molecule tyrosine kinase inhibitors (TKIs) are in clinical development. Areas covered: This review summarizes clinical rationale, mechanisms of action and clinical data for the TKIs under evaluation in the Phase III setting for EOC. Expert opinion: Despite reasonable preclinical activity, small molecule TKIs are unlikely to improve patient survival as single agent therapies in an unselected EOC population. Incorporation of tissue evaluation during ongoing clinical trials is required to identify molecularly defined groups that respond to single agents and direct rational combination strategies based on mechanisms of resistance to improve outcomes in EOC.",
keywords = "angiogenesis, ovarian cancer, Phase III, signaling, targeted therapy, tyrosine kinase",
author = "Klempner, {Samuel J.} and Myers, {Andrea P.} and Gordon Mills and Westin, {Shannon N.}",
year = "2013",
month = "10",
day = "21",
doi = "10.1517/14656566.2013.826650",
language = "English (US)",
volume = "14",
pages = "2171--2182",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

AU - Klempner, Samuel J.

AU - Myers, Andrea P.

AU - Mills, Gordon

AU - Westin, Shannon N.

PY - 2013/10/21

Y1 - 2013/10/21

N2 - Introduction: Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an exquisitely chemo-sensitive disease with response rates of over 75% in the upfront setting. Despite this, due to high rates of recurrence and development of chemo-resistance, the overall survival of EOC remains about 25%. Thus, there is a great need for new therapeutic approaches to render more durable responses. Based on preclinical and early phase clinical studies, key targeted pathways include targets that drive angiogenesis and chemo-resistance. Receptor tyrosine kinases and non-receptor tyrosine kinases play important roles in these processes and several small molecule tyrosine kinase inhibitors (TKIs) are in clinical development. Areas covered: This review summarizes clinical rationale, mechanisms of action and clinical data for the TKIs under evaluation in the Phase III setting for EOC. Expert opinion: Despite reasonable preclinical activity, small molecule TKIs are unlikely to improve patient survival as single agent therapies in an unselected EOC population. Incorporation of tissue evaluation during ongoing clinical trials is required to identify molecularly defined groups that respond to single agents and direct rational combination strategies based on mechanisms of resistance to improve outcomes in EOC.

AB - Introduction: Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and the leading cause of death from gynecologic cancer in the USA. EOC is an exquisitely chemo-sensitive disease with response rates of over 75% in the upfront setting. Despite this, due to high rates of recurrence and development of chemo-resistance, the overall survival of EOC remains about 25%. Thus, there is a great need for new therapeutic approaches to render more durable responses. Based on preclinical and early phase clinical studies, key targeted pathways include targets that drive angiogenesis and chemo-resistance. Receptor tyrosine kinases and non-receptor tyrosine kinases play important roles in these processes and several small molecule tyrosine kinase inhibitors (TKIs) are in clinical development. Areas covered: This review summarizes clinical rationale, mechanisms of action and clinical data for the TKIs under evaluation in the Phase III setting for EOC. Expert opinion: Despite reasonable preclinical activity, small molecule TKIs are unlikely to improve patient survival as single agent therapies in an unselected EOC population. Incorporation of tissue evaluation during ongoing clinical trials is required to identify molecularly defined groups that respond to single agents and direct rational combination strategies based on mechanisms of resistance to improve outcomes in EOC.

KW - angiogenesis

KW - ovarian cancer

KW - Phase III

KW - signaling

KW - targeted therapy

KW - tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84885604991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885604991&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.826650

DO - 10.1517/14656566.2013.826650

M3 - Review article

VL - 14

SP - 2171

EP - 2182

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -